Practice Pearls & Resources for ALK+ NSCLC

EP: 1.Brief Overview & Key Insights: Current Treatment Practices for ALK+ NSCLC

EP: 2.Expert Perspectives on Navigating Biomarker Testing for NSCLC Patients

EP: 3.From Results to Therapy: Preparing Patients for ALK Inhibitor Therapy

EP: 4.Key Considerations for First-Line ALK Inhibitor Treatment Selection

EP: 5.Clinical Perspectives on Managing ALK Inhibitor Adverse Events

EP: 6.Patient Case – Treatment Considerations for ALK+ NSCLC

EP: 7.Monitoring Strategies for ALK Inhibitor Therapy

EP: 8.Patient Education for Long-Term Success on ALK Inhibitor Therapy

EP: 9.Treatment Transitions in ALK+ NSCLC

EP: 10.Long-Term Care in ALK+ NSCLC

Now Viewing

EP: 11.Practice Pearls & Resources for ALK+ NSCLC

The final segment offers practical takeaways for clinicians treating ALK-positive non–small cell lung cancer (NSCLC). Panelists discuss how recent clinical trial data should influence daily practice, particularly in patient monitoring, treatment selection, and adverse effect management. These practice pearls help providers stay current with evolving standards of care.

The segment also encourages advanced practice providers to implement evidence-based tools immediately. These include treatment algorithms, toxicity management protocols, and shared decision-making guides, which improve care consistency and outcomes across settings.

Lastly, the speakers recommend patient-centered resources such as ALKPositive.org, which offers education, advocacy, and community support. Helping patients access reliable information and peer networks strengthens their involvement in care and fosters empowerment throughout their treatment experience.